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Pharmacotherapy of Gestational 




The incidence of gestational diabetes mellitus (GDM) is still rising, and this 
pathological condition is strongly associated with some serious adverse pregnancy 
outcomes. Therefore, GDM must be timely recognized and adequately managed. 
Treatment of GDM is aimed to maintain normal glycemia and it should involve 
regular glucose monitoring, dietary modification, lifestyle changes, moderate 
physical activity, and pharmacotherapy, when necessary. As for the pharmacother-
apy, needed in approximately one-third of GDM women, insulin administration is 
the first choice of pharmacological treatment, although oral hypoglycemic drugs, 
for example, metformin (a biguanide agent) or glyburide (a second-generation 
sulfonylurea drug), could be indicated, too. Metformin is considered as a reason-
able and safe first-line alternative to insulin. If comparing two oral agents, met-
formin seems to be safer than glyburide, since glyburide was found to be linked to 
neonatal hypoglycemia and higher birth weight, which can for example increase 
the hazard for shoulder dystocia and a necessity for Cesarean delivery. Finally, 
it should be underlined that many pregnant women turn to complementary and 
alternative medicine for health maintenance or symptom relief, including tradi-
tional herbal medicine and the use of supplements. Given the previous facts, this 
chapter will address current pharmacotherapy options and challenges related to 
GDM treatment.
Keywords: gestational diabetes mellitus, treatment, insulin, metformin, glyburide, 
oral antidiabetics
1. Introduction
Gestational diabetes mellitus (GDM) is well-described endocrinopathy, refer-
ring to any degree of glucose intolerance that develops or else is initially recognized 
during pregnancy. Today, it is recognized that GDB is most probably a consequence 
of complex and quite diverse interactions between genetic-epigenetic-environmen-
tal factors [1–3]. This diagnosis of gestational diabetes does not include pregnant 
women who have unrecognized pre-existing diabetes, which today accounts for 
about 1% of diabetes cases during gestation [4].
GDM is characterized by aberrant fetoplacental vascular function, insulin 
resistance, and impaired insulin production [5]. Numerous fetal issues have been 
Gestational Diabetes Mellitus - New Developments
2
linked to GDM, for example, macrosomia (birthweight over 4000 g), a higher 
stillbirth risk, birth trauma, a higher percentage of Cesarean delivery, and newborn 
hypoglycemia [6]. Most of these have been particularly positively linked to consid-
erable maternal weight fluctuations in GDM [7]. Although today it has become very 
clear that timely screening and diagnosis (even before 20 weeks gestation) of GDM 
in at-risk women is more than required for clinically desirable maternal and fetal 
outcomes [8], in this context, new predictive and diagnostic biomarkers for GDM 
represent a critical state-of-the-art topic [9].
To circumvent hyperglycemia and its negative effects on fetal growth, 
pregnant women diagnosed with gestational diabetes are initially managed with 
individualized medical nutrition therapy and light exercise. Although the major-
ity of scientific associations propose the thresholds for fasting glucose levels of 
95 mg/dL and 140 mg/dL at 1-h postprandial, recent findings suggested that 
decreasing a threshold for blood glucose at 1 h after a meal to less than  
120 mg/dL in GDM women lowers the risk of large for gestational age infants 
and macrosomia, and at the same time without the increased occurrence of small 
for gestational age infants [10, 11]. This promising finding certainly requires 
further elucidation.
Insulin has generally been recognized as the first-line drug because it is effec-
tive and does not cross the placenta. Other treatment strategies, oral antidiabetic 
drugs (OAD) such as metformin or glyburide, have been used in recent years 
given that insulin therapy has several downsides in GDM. Some of them are the 
absence of a clear dose definition, the need for multiple daily injections, the risk 
of hypoglycemia, and elevated maternal weight gain [12]. Although oral medica-
tions are easy to use and even though they have a high efficacy in the treatment of 
women with GDM, failure to attain glycemic control appears in around 20% of 
women, leaving opportunities for new therapeutic optimization [13]. In accordance 
with previous facts, up-to-date results of available meta-analyses on the effects of 
antidiabetic pharmaceuticals estimated that if we look to the majority of adverse 
neonatal outcomes, metformin was ranked to be the superior treatment over insulin 
or glyburide, whereas the lower risk of adverse maternal outcomes was primarily 
linked to glyburide administration [14]. These divergent effects require additional 
caution in their use [8].
Lots of knowledge has been accumulated regarding GDM screening and timely 
treatment; however, the secondary prevention in women following GDM, as well as 
in their offspring, represents an important scientific challenge for all of us in many 
years to come [15].
In this review, we look at how insulin and other oral hypoglycemic medications 
are used to treat women with GDM, emphasizing on their efficacy and safety. 
Supplement-related and other alternative pharmacotherapy will be addressed, 
as well.
2. Current options of pharmacotherapy in GDB
2.1 Insulin and insulin analogs
2.1.1 Pharmacological properties and use
Insulin, due to its huge molecular size, does not pass the placenta unless at 
extremely high doses [16]. It has a great fetal safety profile; it attains tight maternal 
glucose control and is therefore recommended as a gold standard, and the first-line 
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treatment for women with GDM. Insulin is not teratogenic, and there is also no 
evidence that any of them are excreted in human milk [17].
Currently, available insulin analogs are rapidly acting analogs, including aspart 
and lispro, short-acting regular insulin, intermediate-acting NPH insulin, or 
longer-acting insulin analogs, such as glargine and detemir [18, 19].
Insulin is the therapy of choice for women who have failed to meet their 
glycemic treatment goals despite making lifestyle changes—diet and exercise 
[2]. It can also be used by those who are unable to tolerate the adverse effects of 
other OADs.
The dose and timing of insulin use are determined by the women’s body weight, 
gestational age, and the time of day when hyperglycemia occurs. Insulin dosage is 
modified often during pregnancy based on blood glucose values, hypoglycemia, 
physical activity, nutritional intake, infection, and patient’s compliance.
Based on the time of recurrent hyperglycemia, there are two major ways of 
prescribing insulin. Insulin can be given in divided doses throughout the day or as 
a single daily dose. Intermediate insulin, such as NPH or detemir, should be given 
as a single dose at bedtime in GDM women who have hyperglycemia solely in the 
morning fasting state. Rapid-acting insulin should be administered before a meal 
in women who have postprandial hyperglycemia. Hyperglycemia during the day 
should be controlled with a combination of intermediate- or long-acting and short-
acting insulin [20].
Close blood glucose monitoring is required while prescribing insulin to avoid 
hypoglycemia or hyperglycemia. GDM women should bring their self-monitored 
blood glucose logs to the doctor’s office so that the insulin regimen can be adjusted 
when necessary.
2.1.2 Efficacy and safety
Rapid-acting insulin analogs, often known as bolus insulin, are used to imitate 
endogenous insulin’s response to meal intake. They reach a concentration peak 
sooner than regular insulin and show a shorter duration of action (3–5 h) [21]. In 
comparison with human insulin, which must be administered 30 minutes before a 
meal, rapid-acting insulin analogs can be given 5–10 minutes before a meal, mak-
ing them more convenient [22]. Basal insulin, also known as intermediate-acting 
and long-acting insulin, is primarily used to give a constant supply of the modest 
amounts of insulin to regulate lipolysis and avoid hepatic gluconeogenesis, regard-
less of meal intake.
Although insulin treatment has traditionally been the drug of choice for treat-
ing hyperglycemia in GDM after medical nutrition and physical exercise, it is not 
without limitations. Many pregnant women face issues with insulin administration, 
including gaining weight, balancing dosage, diet, and, for some, the frequency of 
hypoglycemic episodes. For that reason, there are quite a few reports currently sug-
gesting metformin as the first-line agent having an equivalent efficacy vs. insulin, 
yet with less hypoglycemia than insulin [23].
Short-acting insulin has been connected to an augmented risk of hypoglycemia 
and glycemic control changes in those with GDM. Aspart’s recent experience 
has been positive, although lispro has been linked to higher birth weight and a 
greater rate of large for gestational age newborns [24]. In randomized clinical 
investigations comparing detemir to NPH for intermediate- and longer-acting 
insulin, there was no difference in glucose management or perinatal outcomes. 
Detemir has been linked to a lower risk of hypoglycemia in diabetics who are not 
pregnant [25].
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2.2 Oral antihyperglycemic drugs (OAD)
2.2.1 Metformin
2.2.1.1 Pharmacological properties and use
Metformin, an oral biguanide, works by reducing liver gluconeogenesis, increas-
ing peripheral insulin sensitivity, and also promoting glucose uptake in peripheral 
tissues while lowering glucose absorption in the gut [26]. Several mechanisms 
are responsible for higher insulin sensitivity including the augmented activity of 
insulin receptor tyrosine kinase, enhanced synthesis of glycogen, reduction of gly-
cogenolysis, decreased activity of hepatic glucose-6-phosphatase, and an increase 
in the recruitment and activity of GLUT4 glucose transporters [27]. It decreases 
fasting serum insulin by 40% (thus lowers the risk of hypoglycemia) and leads to 
a 5.8% weight loss on average [28]. Despite identical glycemic control, metformin 
was related to lower cardiovascular, as well as all-cause mortality if paralleled to 
sulphonylureas and insulin in a long-term prospective study of type 2 diabetes. The 
RISK pathway activation via increased AMPK activity may be responsible for this 
effect [29, 30].
Organic cation transporters (OCTs) transport metformin across the mito-
chondrial membrane at the cellular level. Since the placenta expresses many OCT 
isoforms, metformin crosses the placenta easily during pregnancy. Concerns 
about potential negative effects on fetal development arise from transport via the 
placenta into the developing fetus. Although it is unknown if OCTs are expressed 
in human embryos, we know that pre-implantation human embryos have limited 
mitochondrial capacity making them resistant to metformin [31, 32]. In Metformin 
in gestational diabetes study (MiG), children (aged 2) exposed to metformin during 
pregnancy were compared to children of the same age whose mothers were on 
insulin during pregnancy. Children exposed to metformin had comparable overall 
body fat, yet more subcutaneous fat over intra-abdominal fat compared to children 
exposed to insulin, thus suggesting that metformin treatment may lead to a more 
advantageous pattern of fat distribution than insulin [33].
Only recently there has been evidence to support the use of metformin for the 
management of GDM. It has, however, been used in early pregnancy and all through 
pregnancy for additional indications for decades. Metformin can help women with 
the polycystic ovarian syndrome to establish regular ovulation and to enhance 
conceiving odds, and by using it during the first trimester to lower the incidence of 
spontaneous abortion [34]. Metformin’s use and effectiveness in the management of 
insulin-dependent T2DM in pregnancy have been supported by early research [35]. 
Despite this, it was not until the metformin in Gestational Diabetes trial, presented 
by Rowan et al. in 2008, was widely reported as an effective treatment for GDM [36].
2.2.1.2 Efficacy and safety
In the gestational diabetes trial [36], women were randomly assigned to either 
metformin or standard treatment, that is, insulin. Supplemental insulin was 
required by a large percentage of women using metformin (46%), however at much 
lower doses than GDM-women using insulin as monotherapy. The key outcome 
was a combination of neonatal hypoglycemia (2.6 mmol/L), respiratory distress, 
requirement for phototherapy, 5-minute Apgar score of 7, or premature birth 
(before 37 weeks), and it was similar in both treatment groups. Women who took 
metformin gained considerably less weight from enrolment to term than those who 
took insulin. Other parameters considered in the metformin and insulin clusters 
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were similar, including birth weight, neonatal anthropometrics, and odds for large 
for gestational age. However, when compared to insulin therapy, the incidence of 
severe hypoglycemia (1.6 mmol/L) was lower in the metformin group. This research 
also discovered that patient acceptability for metformin was substantially better 
than with insulin; when questioned if they would select it yet again for future preg-
nancies, 77 percent of metformin users replied yes, compared to only 27 percent of 
insulin users. Metformin’s gastrointestinal side effects caused 32 women (8.8%) to 
cut their dose, although only 7 (1.9%) had to discontinue taking it.
A group of 100 GDM women merely treated with metformin vs. 100 women 
with GDM only treated with insulin were matched for age, weight, and ethnicity in 
a case–control observational study [37]. Maternal risk factors were similar in both 
groups. The rates of preeclampsia, prenatal hypertension, and Cesarean section 
were identical, but an average maternal gain of weight from enrolment to term was 
considerably lower in the metformin group, just as it was in the MiG study. When 
compared to women who were treated with insulin, women who were given met-
formin had a lower rate of preterm, neonatal jaundice, and admission to a neonatal 
unit, as well as an overall improvement in newborn morbidity [37].
Post-prandial glycemic levels may indeed be of importance when comparing 
metformin to other treatment options. A meta-analysis of three randomized con-
trolled studies of GDM women found lower post-prandial glucose in metformin as 
opposed to insulin-treated patients, though these disparities did not meet statistical 
significance [38].
Metformin did not raise the risk of preterm delivery or Cesarean section, as 
reported in a latest systematic review, nor did it raise the risk of small for gesta-
tional age newborns. Metformin, on the other hand, was linked to a lower risk of 
preterm birth, newborn hypoglycemia, and admission to neonatal intensive care 
units, as well as a decreased prevalence of pregnancy-induced hypertension [39].
Because metformin is not stimulating the secretion of insulin, it does not 
provoke maternal hypoglycemia, which is a side effect that remains a concern with 
glyburide. For the same reason, severe neonatal hypoglycemia is less likely to occur 
after metformin administration compared to insulin [14]. Accordingly, hypoglyce-
mia is a greater risk if taking insulin, than with OAD [40]. Metformin, on the other 
hand, crosses the placental barrier easily due to its low molecular mass, hydrophilic 
nature, and lack of protein binding [41]. Metformin concentrations in the fetus are 
likely minimal and no fetal side effects, such as congenital malformations, have 
been detected [42]. It is not thought to be teratogenic, as evidenced by decades of 
use in preconception and early pregnancy. There have been no reports of newborn 
lactic acidosis, and neonatal hypoglycemia has been related to maternal hypergly-
cemia during delivery rather than a direct side effect of metformin. It belongs to the 
FDA’s Pregnancy Category B.
Before starting metformin treatment, patients should be informed about the 
potential for maternal adverse effects. Although its mechanism of action does not 
produce hypoglycemia directly, symptoms are observed in 0–10% of women who 
administered the drug. A 5 percent to 15% of women experienced gastrointestinal 
side effects, such as flatulence, nausea, diarrhea, and vomiting. Lactic acidosis, the 
most worrying potential side effect, was prevented by gradually raising the dose [43].
One final question could be certainly related to the eventual advantageous 
co-administration of metformin and insulin in GDM. Scarce reports have been 
published over the past decade; however, Chaves et al. [44] recently addressed this 
issue through the retrospective investigation with an evaluation of the Portuguese 
National Registry of GDM (2012–2017) with a very interesting report that in GDM 
women the concomitant use of metformin and insulin resulted in comparable obstet-
ric and neonatal adverse events if paralleled with insulin monotherapy. Moreover, 
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the authors reported that expected beneficial effects on weight gain and insulin dose 
were simply not detected if both drugs were used in a parallel manner [44].
2.2.2 Glyburide
2.2.2.1 Pharmacological properties and use
Glyburide is a second-generation sulfonylurea that acts mainly by increasing 
the secretion of insulin from the pancreas and improving the insulin sensitivity 
of peripheral tissues. These actions can be detected after a block of the sulfonyl-
urea receptor, which is actually a part of the ATP-sensitive potassium channel in 
the pancreatic beta cells [45]. Glyburide is lipophilic and significantly bound to 
albumin [46].
At first, it was assumed that glyburide did not cross the placenta. Langer et al. 
(2000) did not detect glyburide in umbilical cord serum of neonates whose mothers 
were taking glyburide during pregnancy, thus confirming in vitro investigations 
that found no glyburide transfer in-between mother and fetus. The reason behind 
that is that they used liquid chromatography with a limit of detection of 10 ng per 
milliliter [13]. Newer studies proved that glyburide can be found in umbilical cord 
serum by using a highly sensitive liquid chromatography-mass spectrometry test for 
determining glyburide at sub-ng/mL levels, confirming that glyburide is actually 
transferred transplacentally [47].
There is an obvious option to glyburide and that is insulin administration. Even 
though glyburide is an FDA category C drug, compared to insulin analogs (lispro, 
detemir, and aspart) that are all pregnancy risk factor B medications, glyburide is 
still widely used. The situation where glyburide is a better choice is where self-mon-
itoring of glucose blood levels needed for insulin or insulin storage is not possible or 
where a patient has a severe needle phobia.
Another benefit of using glyburide is that it is a low-cost oral agent, easy to 
take with few side effects. Also, glyburide is, as an oral agent just like metformin, 
easier to use compared to insulin [41]. Nevertheless, the other use of glyburide 
during pregnancy for GDM patients is still unclear and needs to be comprehensively 
elucidated [48].
2.2.2.2 Efficacy and safety
The New England Journal of Medicine published a clinical investigation compar-
ing glyburide versus insulin in management of GDM in 2000, which transformed 
the management of GDM. Namely, Langer et al. (2000) conducted the first ran-
domized, controlled study where they compared glyburide to insulin by dividing 
404 women with GDM into two groups, 201 receiving glyburide and 203 receiving 
insulin [49]. Results did not show any significant difference between the two 
clusters in neonatal outcomes by measuring high blood glucose concentrations, 
the incidence of macrosomia, admission to neonatal intensive care unit, etc. The 
authors also noted that the extent of glycemic control between the two groups was 
similar. A different study comparing macrosomia, neonatal hypoglycemia, and 
hyperbilirubinemia in two groups found no evidence that using glyburide instead of 
subcutaneous insulin leads to a higher rate of perinatal problems [50]. On the con-
trary, a retrospective cohort study analyzed data from 9173 women diagnosed with 
GDM and treated with glyburide opposite to insulin 150 days before delivery [37]. 
It was found that newborns delivered by women treated with glyburide were more 
expected to have complications than those delivered by mothers who were taking 
insulin. Complications noted were preterm birth, Cesarean delivery, hypoglycemia, 
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respiratory distress, jaundice, birth injury, large for gestational age, and hospitaliza-
tion in the neonatal ICU [51].
Seven trials comparing glyburide (n = 457) to insulin (n = 467) were analyzed in 
one more recent meta-analyses by Jiang et al. to assess the efficacy and safety of oral 
anti-diabetic (OADs) medicines for GDM. In terms of glycemic management, the 
investigators did not find any difference between glyburide and insulin. Glyburide 
therapy, on the other hand, is linked to a higher risk of neonatal hypoglycemia, high 
neonatal birth weight, high maternal weight gain, and macrosomia [52].
A group of 457 glyburide-managed pregnancies and 467 insulin-treated preg-
nancies were evaluated in the Jiang meta-analysis comparing the efficacy and safety 
of OAD for GDM [52]. Despite no dissimilarity in glycemic control, the authors 
found that glyburide caused considerably more macrosomia than insulin (OR: 3.09, 
95% CI: 1.59–6.04, P = 0.009). Glyburide was also associated with a greater rate 
of newborn hypoglycemia than insulin (OR: 2.64, 95% CI: 1.59–4.28, P = 0.0002). 
There was no difference in weight growth, Cesarean delivery rate, or preeclampsia 
between NICU admissions or premature births.
Finally, it has to be underlined that glyburide was ranked the worst in the 
recent meta-analysis, with the highest rates of macrosomia, hyperbilirubinemia, 
preeclampsia, neonatal hypoglycemia, low birth weight, preterm birth, and met-
formin (plus insulin when needed) had the lowest rates of pregnancy hypertension, 
macrosomia, LGA, RDS, preterm birth, and low birth weight [53]. Besides, one 
has to be very cautious with glyburide use, which was shown to be associated with 
weight gain, as well as maternal hypoglycemia, especially when taken without any 
food [45].
2.2.3 Acarbose
2.2.3.1 Pharmacological properties and use
Acarbose is an alpha-glucosidase inhibitor, which means it prevents enzymes 
found on the small intestine’s brush border from breaking down complex starches 
into oligosaccharides and oligosaccharides, trisaccharides, and disaccharides into 
glucose. As a result, the rise in postprandial glucose concentrations is lowered. Its 
use is usually linked to gastrointestinal complications. Although just 2% of acar-
bose is absorbed as an active medication, 34% of its metabolites were found in the 
systemic circulation [54].
Acarbose is not usually recommended for the treatment of GDM, because it has 
not been thoroughly researched during pregnancy and considering safer and more 
acceptable options, with more information regarding treating GDM, such as insulin 
and metformin.
2.2.3.2 Efficacy and safety
One small randomized prospective study (n = 70) in Brazil compared glyburide 
and acarbose to insulin in the treatment of GDM and showed the absence of 
notable differences in fasting or postprandial glucose concentrations with acarbose, 
although gastrointestinal side effects were higher in occurrence with acarbose [55]. 
Acarbose showed a higher failure rate (42%) in establishing glycemic control com-
pared to glyburide (21%). Neonatal hypoglycemia occurred in one acarbose-treated 
subject, one insulin-treated subject, and eight glyburide-treated subjects. Only four 
neonates (16%) developed macrosomia, which is after receiving glyburide therapy.
Although in this short trial, failure to achieve glycemic control with acarbose 
was higher if compared to glyburide, the decreased incidence of hypoglycemia and 
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macrosomia underlines acarbose as an appealing agent to investigate in future GDM 
treatment studies. Accordingly, in the recent investigation published by Jayasingh  
et al. (2020), it was proposed that acarbose can be seen as an effective and 
adequately tolerated choice for the management of GDM [56]. Namely, this pro-
spective, open-label, and controlled study was designed to compare the fetoma-
ternal outcomes in pregnant women with GDM designated to insulin or acarbose 
group. Thus, no difference was found if the following parameters were paralleled 
in between the groups: the incidence of recurrent infections, preeclampsia, or 
premature rupture of membranes; then the modes of delivery, mean postoperative 
random blood glucose, fasting blood glucose level at day 7 and after 6 weeks; and 
finally difference in the mean birth weight of offspring born to mothers treated 
with either of the two pharmacological agents.
Even though using acarbose in diabetic patients has been linked to abnormal 
liver enzymes and hepatic failure, a newer study did not show a higher risk of liver 
injury during acarbose treatment [57]. Acarbose can pass through the placenta. In 
pregnant animal investigations, doses up to 32 times higher than the human dose 
were not proven to be teratogenic. On the other hand, it induces stomach cramps 
and may raise prostaglandin E, suggesting that it possess the potential ability to 
induce labor [58].
3. Supplementation and traditional treatment options
The efficacy of vitamin and mineral supplementation in GDM patients is still 
under investigation. However, today is known that in GDM, low levels of vitamin D,  
vitamin E, and magnesium have been detected, whereas glucose metabolism, anti-
inflammatory, and anti-oxidative stress have been all positively regulated after 
vitamin D, vitamin E, magnesium, and selenium supplementation, which was also 
confirmed in the very recent meta-analysis reported by Li et al. [59]. In the same 
manner, 6-week-long Mg-Zn-Ca-vitamin D co-supplementation reduced biomarkers 
of inflammation and oxidative stress in GDM women [60]. To continue, the improve-
ment in glycemic control and decline of adverse fetomaternal outcomes after  
vitamin D supplementation (including Cesarean section, postpartum hemorrhage, 
maternal hospitalization, neonatal hyperbilirubinemia, giant children, fetal distress, 
polyhydramnios, premature delivery) was underlined by Wang et al. [61].
Dietary adjustments accompanied with lifestyle modifications are known to 
achieve normoglycemia in a majority of women with GDM, especially underlining 
careful attention to type and amount of dietary carbohydrates [62]. In this context, 
myoinositol, a dietary supplement knowing to decrease insulin resistance, became 
extensively investigated [63]. It represents inositol isomer organically present for 
example in legumes or nuts, but also synthesized in kidneys and liver to a certain 
extent. Accordingly, recent findings pointed out that, if started shortly after the 
GDM diagnosis, myoinositol (1000 mg twice daily, per os) was shown to be effec-
tive in reaching glycemic control and reducing the need for additional pharmaco-
therapy [64].
Traditional Chinese medicine and herbal products, known to be broadly utilized 
during human history, now belong to a very interesting field currently investigated 
in the frame of GDM [65]. So far, herbs such as Zuo Gui Wan, red raspberry tea, and 
Orthosiphon stamineus all provided valid possibilities in reducing glucose and alle-
viating the GDM-related pathophysiology, and at the same time with good safety 
profile to the mother and neonate [66]. In addition, the antidiabetic potential of 
glycyrrhiza flavonoids from traditional Chinese medicine, as adjuvants for insulin 
therapy, could be especially beneficial in GDM [67].
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Finally, probiotics supplementation in improving glycemic control and attenuat-
ing some of the adverse events related to GDM is a very interesting and appealing 
scientific issue that needs further elucidation [68, 69].
Even though new and promising results are published every day, novel investiga-
tions and, most of all, well-designed standardized protocols are needed for obtain-
ing original, comparable, and sustainable results in this field of adjuvant GDM 
treatment.
4. Conclusions
In the twenty-first century, GDM poses a significant challenge to health care 
professionals. The short- and long-term effects of successfully controlling GDM 
are important for both the mother and the fetus. This chapter provided data related 
to proposed pharmacological treatment options for GDM, further evaluating each 
therapy’s unique characteristics, benefits, and drawbacks in comparison with the 
alternatives. Most guidelines recommend oral pharmacological therapy, such as 
glyburide and metformin, and it is now widely used, with data on efficacy and 
safety. They can both be used as the first-line option; however, metformin appears 
to be preferable to glyburide in terms of newborn and maternal outcomes, while 
it is associated with a higher incidence of failure to achieve appropriate glycemic 
control. Analogs such as detemir, aspart, and lispro, which have been thoroughly 
proved for their safety and efficacy during pregnancy, are indicated as first-line 
therapy or when oral medication fails to achieve optimal glucose control. Glargine 
can be used during pregnancy, while there is not as much data to back it up as there 
is for other long-acting analogs and human insulins.
Therefore, the pharmacological treatment for GDM should be adapted to the 
patient’s characteristics, glycemic profile, and preferences, as well as local profes-
sional body guidelines. While insulin has typically been used to treat GDM, both 
metformin and glyburide may be used, but patients should be informed about the 
risks and advantages.
Pharmacotherapy of GDM is still under investigation, even though much is 
known about GDB itself. We can witness that the molecular understanding of GMB 
has been constantly translated to more efficacious and safer therapeutic options. 
Still, we expect that coordinated and well-focused basic and clinical investigations 
will provide even more precise information regarding future choices for prevention 
and adequate, as well as timely treatment of GDM.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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